STOCKHOLM, July 27, 2018 /PRNewswire/ -- Second
quarter
- Revenue increased by 13.8% to €161.1m (€141.6m). Organic
revenue grew by 13.7%.
- Operating profit amounted to €6.4m (€5.7m), representing an
operating margin of 4.0% (4.0%).
- Net profit amounted to €7.0m (€2.3m), which represents a net
profit margin of 4.3% (1.6%).
- Cash flow from operating activities amounted to €7.3m
(€8.9m).
- Basic/diluted earnings per share (EPS) were €0.050
(€0.016).
- EBITDA increased by 10.7% to €13.5m (€12.2m), corresponding to
an EBITDA margin of 8.4% (8.6%).
First half
- Revenue increased by 13.9% to €323.0m (€283.5m). Organic
revenue grew by 14.0%.
- Net profit amounted to €16.4m (€6.7m), which represents a net
profit margin of 5.1% (2.4%).
- EBITDA increased by 12.2% to €28.5m (€25.4m), corresponding to
an EBITDA margin of 8.8% (9.0%).
REVENUE AND EARNINGS
|
€ millions
(€m)
|
Q2
2018
|
Q2
2017
|
Growth
|
6M
2018
|
6M
2017
|
Growth
|
FY
2017
|
|
Revenue
|
161.1
|
141.6
|
14%
|
323.0
|
283.5
|
14%
|
580.2
|
|
Operating
profit
|
6.4
|
5.7
|
12%
|
14.5
|
12.5
|
16%
|
28.8
|
|
Operating profit
margin, %
|
4.0%
|
4.0%
|
|
4.5%
|
4.4%
|
|
5.0%
|
|
Net profit
|
7.0
|
2.3
|
204%
|
16.4
|
6.7
|
145%
|
20.2
|
|
Net profit margin,
%
|
4.3%
|
1.6%
|
|
5.1%
|
2.4%
|
|
3.5%
|
|
Earnings per share,
€
|
0.050
|
0.016
|
213%
|
0.117
|
0.054
|
117%
|
0.157
|
|
Diluted earnings per
share, €
|
0.050
|
0.016
|
213%
|
0.117
|
0.054
|
117%
|
0.157
|
|
|
|
|
|
|
|
|
|
EBITDA
|
13.5
|
12.2
|
11%
|
28.5
|
25.4
|
12%
|
55.0
|
|
EBITDA margin,
%
|
8.4%
|
8.6%
|
|
8.8%
|
9.0%
|
|
9.5%
|
For Alternative Performance Measure definitions and
reconciliations, refer to note 7.
This information is information that Medicover AB is obliged to
make public pursuant to the EU Market Abuse Regulation and the
Securities Markets Act. The information was submitted for
publication, through the agency of the contact person set out
below, at 8.00 (CEST) on 27 July
2018. This interim report and other information about
Medicover, is available at medicover.com.
For further information, please contact:
Paula
Treutiger
Corporate Communications & Investor Relations,
Director
Phone: +46-73-66 6599
Mail: paula.treutiger@medicover.com
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/medicover/r/interim-report-april-june-2018,c2582213
The following files are available for download:
|
http://mb.cision.com/Main/15662/2582213/883653.pdf
|
Interim report
April-June 2018
|
